Shree Ganesh Remedies Limited (NSE:SGRL)

Market Cap	9.43B +33.9%
Revenue (ttm)	989.78M -8.8%
Net Income	154.35M -29.4%
EPS	12.01 -29.4%
Shares Out	n/a
PE Ratio	61.10
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,697
Open	705.10
Previous Close	704.80
Day's Range	705.10 - 749.85
52-Week Range	490.00 - 740.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 8, 2026

About Shree Ganesh Remedies

Shree Ganesh Remedies Limited engages in the manufacture and sale of pharmaceutical drug intermediates for active pharmaceutical ingredient (API) and fine chemicals in India and internationally. The company offers anti-arrhythmic, anti-cancer, anti-depressant, anti-diabetic, anti-diarrheal, antifungal, antihistamine, anti-inflammatory, anti-parasitic, anti-psychotic, anticholinergic, birth-control, cardiovascular, gastrointestinal, neurological disorder, ophthalmic, opioid, and veterinary API intermediates. It also provides fine and specialty c...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 224
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SGRL

Financial Performance

In fiscal year 2026, Shree Ganesh Remedies's revenue was 1.09 billion, an increase of 0.63% compared to the previous year's 1.09 billion. Earnings were 177.60 million, a decrease of -23.01%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 24, 2026

Data Sources Report a data error